

Session #	Session Title	Session Date	Session Time	Place	Presentation Time	First Name	Last Name	Country/District	Title of Abstract
Parallel Session 1	Epidemiology & Clinical Predictors 1	Thursday Oct. 2	9:00-9:30	Room 3 "606"	09:00-09:10	Jordan	Low	Singapore	Gender-Specific Body Composition Phenotypes Predict Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis: A Cross-Sectional MRI-Based Clustering Analysis
					09:10-09:20	Yoshiko	Nakamura	Japan	Pathological Classification of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Based on Muscle Fatty Changes and Quantitative Changes Using MRI: A Cluster Analysis Study
					09:20-09:30	Liu	Jing	China	Metabolic-associated fatty liver disease: Research advanced in Epidemiology, Risk factors, and precision prevention and control strategies in China
Parallel Session 2	Epidemiology & Clinical Predictors 2	Thursday Oct. 2	9:30-10:00	Room 3 "606"	09:30-09:40	Seohui	Jang	Korea	Dynamic Changes in Steatotic Liver Disease Subtypes and Risk of Cardiovascular Disease: A Nationwide Cohort Study
					09:40-09:50	Jeongin	Lee	Korea	The Risk of Heart Failure in Patients with Atrial Fibrillation According to the Steatotic Liver Disease Subtype
					09:50-10:00	Sangwook	Cheon	Korea	Risk Factors for Cardiovascular Disease Among Older Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Cohort Study
Parallel Session 3	Epidemiology & Clinical Predictors 3	Thursday Oct. 2	10:05-10:35	Room 3 "606"	10:05-10:15	Kamal	Parvej	Bangladesh	Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Angiographic Severity of Coronary Artery Disease in Acute Coronary Syndrome
					10:15-10:25	Tiansu	Lv	China	Potential Targets in Metabolic-Associated Steatohepatitis Based on Bioinformatics Analysis and Machine Learning Strategies
					10:25-10:35	Tatia	Khachidze	Georgia	Gut Microbiota Dysbiosis and Its Role in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease
Parallel Session 4	Epidemiology & Clinical Predictors 4	Thursday Oct. 2	10:35-11:05	Room 3 "606"	10:35-10:45	Jin Hyeok	Choi	Korea	Association of Combustible Cigarette and Noncombustible Tobacco Product Use With Mental Health Outcomes in Subtypes of Fatty Liver Disease: A Nationwide Cohort Study From Korea
					10:45-10:55	Jin-Hyun	Park	Korea	Handgrip Strength Estimation as a Predictor of Liver-Related Outcomes in Patients with Steatotic Liver Disease
					10:55-11:05	Seokjin	Kong	Korea	Differential Effects of Antihypertensive Drug Classes on Liver-related Outcomes in MASLD/MetALD Patients with Hypertension
Parallel Session 5	Epidemiology & Clinical Predictors 5	Thursday Oct. 2	13:00-13:30	Room 3 "606"	13:00-13:10	Vikas	Sharma	India	AI-Integrated Biosensor Wearables for Monitoring Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Type 1 Diabetes
					13:10-13:20	Vikas	Sharma	India	The Role of Wearable Technology and Geo-Fencing in Physiological Monitoring and Pre-Transplant Optimization for Adolescents with NAFLD Undergoing Bariatric Surgery
					13:20-13:30	Yutian	Cao	China	Sex and Menopausal Differences in the Association between Visceral Adipose Tissue and Metabolic Dysfunction-associated Steatotic Liver Disease: A Cross-sectional and Mendelian Randomization Study
Parallel Session 6	Mechanisms & Injury 1	Thursday Oct. 2	13:30-14:10	Room 3 "606"	13:30-13:40	Noriyoshi	Ogino	Japan	Neutrophil Elastase Undergoes Endocytosis into Hepatocytes and Contributes to Liver Injury in Alcoholic Hepatitis
					13:40-13:50	Yichu	Kao	Taiwan	IL-1R1 Deficiency Attenuates Hepatic Ischemia-Reperfusion Injury by Coordinating Oxidative Stress Control, Hepatocyte Regeneration, and Immune Rebalancing
					13:50-14:00	Nguyen	Bui Tam Chi	Japan	Role of Recombinant Human Cytochrome P450 2E1 against Acetaminophen-induced Liver Injury
					14:00-14:10	Mengyi	Shen	China	Engineering Vesicle-Mediated Metabolic Regulation and Immune Targeting for the Treatment of Autoimmune Hepatitis
Parallel Session 7	Mechanisms & Injury 2	Thursday Oct. 2	14:10-14:50	Room 3 "606"	14:10-14:20	Balasubramanian	Vairappan	India	Pharmacological Inhibition of Hepatic DGAT2 Reduces Triglyceride Synthesis and Attenuates MAFLD Progression in Mice
					14:20-14:30	Fawaz	Haj	USA	Deficiency of Hepatic Protein Tyrosine Phosphatase 1B is Protective in a Mouse Model of MASH
					14:30-14:40	Michiko	Ishii	Japan	Development and Characterization of a Murine Model of Anorexia Nervosa-Associated Microvesicular Steatosis
					14:40-14:50	Sunita	Giri	India	Deregulation of FTO Isoforms in the Progression of Nonalcoholic Fatty Liver Disease to Nonalcoholic Steatohepatitis and its Amelioration with Entacapone
Parallel Session 8	Mechanisms & Injury 3	Thursday Oct. 2	14:50-15:20	Room 3 "606"	14:50-15:00	Zhe	Cheng	China	Xietu Hemu Prescription Suppresses Adipocytogenesis and Alleviates Dysregulation of Lipid Metabolism in Vitro through LEP/AMPK/PPARG Axis
					15:00-15:10	Weilong	Xu	China	Myricetin Ameliorates MASLD by Enhancing Mitochondrial Function and Promoting PINK1/Parkin-dependent Mitophagy
					15:10-15:20	Navia	Vinoy	Australia	A Novel PEX13 Knockout Liver Cell Line Generated Using CRISPR Prime Editing Provides New Insights into Steatotic Liver Disease
Parallel Session 9	Fibrosis 1	Thursday Oct. 2	16:40-17:10	Room 3 "606"	16:40-16:50	Selvakumar	Vigneshwaran	Singapore	A Proof of Concept for Ultrasound Based Artificial Intelligence Quantification of Liver Steatosis and Fibrosis
					16:50-17:00	Mark D	Gorrell	Australia	A Novel Fibrosis NIT that Uses the Myofibroblast Marker Fibroblast Activation Protein (FAP) and FIB4 in Metabolic Associated Steatotic Liver Disease
					17:00-17:10	Taisei	Iwasa	Japan	Development of Overt Hepatic Encephalopathy Increases Mortality in Patients with Cirrhosis: A Multicenter Retrospective Cohort Study
Parallel Session 10	Fibrosis 2	Thursday Oct. 2	17:10-17:40	Room 3 "606"	17:10-17:20	Michitaka	Matsuda	Japan	Wilms Tumor 1 Induces Hepatic Stellate Cell Invasion that Develops Bridging Fibrosis in Chronic Liver Injury
					17:20-17:30	Masahiro	Yanagi	Japan	Effects of Hydroxynonenal on Hepatic Macrophages in the Pathogenesis of MASLD
					17:30-17:40	Ji	Sun	China	DHX9 Loads Hepatocyte-derived Exosomal miR-106b to Activate Hepatic Stellate Cells via Actin Cytoskeleton in MASLD
Parallel Session 11	Fibrosis 3	Friday Oct. 3	13:10-13:40	Room 2 "Orion"	13:10-13:20	Jiaying	Wang	China	Mechanism of TRPML1 in MAFLD: AMPK-Mediated Regulation of Autophagy and Lipid Metabolism
					13:20-13:30	Mona	Munteanu	USA	Noninvasive Initiation and Monitoring of the Therapy with TNR-beta Agonist Resmetirom (RT) Using LIVERFASt (LFAST), FIB-4 and Vibration-controlled Transient Elastography (VCTE, Fibroscan) in Patients with MASH
					13:30-13:40	Lin	Guan	China	Non-targeted Metabolomics Sequencing Combined with 101 Machine Learning Algorithms to Analyse Key Metabolites in Varying Degrees of Non-alcoholic Fatty Liver Disease
Parallel Session 12	Carcinogenesis 1	Friday Oct. 3	13:40-14:10	Room 2 "Orion"	13:40-13:50	Jun	Arai	Japan	Natural Killer Activating Receptor Ligands are Promising Biomarkers to Predict the Pathogenesis of At-risk MASH
					13:50-14:00	Hongping	Xia	China	Understanding the Microenvironment and Progression of Liver Fibrosis to Cancer for Developing Novel Precision Therapy
					14:00-14:10	Tomoo	Yamazaki	USA	Single Nuclei RNA Sequencing Shows the Engagement of PPARG Target Genes Primarily in Hepatocytes and Cholangiocytes by the Selective PPAR-delta Agonist Seladelpar
Parallel Session 13	Carcinogenesis 2	Friday Oct. 3	16:15-16:45	Room 2 "Orion"	16:15-16:25	Jirayu	Sriphaiboon	Thailand	Clinical Significance of Leptin Receptors and Promoting Roles of Leptin in Hepatocellular Carcinoma
					16:25-16:35	Yuki	Matsushita	Japan	The Risk of Decompensation in Steatotic Liver Disease-related Hepatocellular Carcinoma after Curative Treatment
					16:35-16:45	Mohamed	Abdel-Samee	Egypt	Micro-RNA Gene Polymorphisms and Development of Hepatocellular Carcinoma in Egyptian Patients with Chronic Viral Hepatitis